[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menstrual-cramps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menstrual-cramps":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100606532","effect-of-semiconductor-embedded-wearable-sleeve-on-treatment-of-primary-dysmenorrhea-symptoms-100606532",false,"NCT07176780","Effect of Semiconductor Embedded Wearable Sleeve on Treatment of Primary Dysmenorrhea Symptoms","Effect of Semiconductor Embedded Wearable Sleeve on the Treatment and Mitigation of Primary Dysmenorrhea Symptoms: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Self-reported primary dysmenorrhea during past three menstrual cycles\n* Age 18-45 inclusive at the time of consent\n* Self-reported typical primary dysmenorrhea symptom pain greater than 4 on a 1-10 visual analog scale (VAS)\n* History of regular menstrual cycles with a usual length of 21 to 35 days\n* Willing and able to provide informed consent and adhere to study requirements\n\nExclusion Criteria:\n\n* History of neurological conditions, including multiple sclerosis or Parkinson's disease\n* Secondary dysmenorrhea including confirmed or suspected endometriosis or fibroids or intrauterine device\n* Self-reported size not available in study device\n* Pregnant or planning to become pregnant during the study\n* Have within the past six months of enrollment, or are planning to in the next six months, start or discontinue any of the following contraceptive methods:\n\n  1. intrauterine device\n  2. oral contraceptives,\n  3. contraceptive patch,\n  4. implant (Nexplanon),\n  5. shot (Depo-Provera),\n  6. vaginal ring\n* Chronic pain conditions unrelated to primary dysmenorrhea\n* Auto-immune or auto-inflammatory diseases\n* Has used within the last 90 days or is planning to use nicotine-containing products\n* History of metabolic disorders\n* Active infection (local or systemic) that, in the opinion of the investigator, would prevent usage of the device\n* In the opinion of the investigator, any other criteria or condition that could increase the risk associated with study participation or study treatment or could interfere with the interpretation of study results\n* Have taken any investigational drug or used any investigational device within the 30 days prior to consent.",true,"FEMALE","18 Years","45 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is looking to test a non-compressive semiconductor embedded body sleeve for treatment of primary dysmenorrhea symptoms. Dysmenorrhea is the lower abdominal pain (sometimes referred to as \"cramping\") experienced during menstruation (monthly \"period\"), affecting up to 94% of people aged from 10-20 years old. The semiconductor embedded fabric increases blood circulation through activation of the embedded elements with body heat while worn and releases energy waves as well as negative ions. This energy has an effect inside the body that increases oxygen and nutrient flow to tissues, and can help to decrease pain and inflammation. This study is testing this technology to see if it can be used as a non-pharmacological treatment for menstrual cramping.",[28,29,30,31],"Primary Dysmenorrhea","Primary Dysmenorrhea (PD)","Menstrual Cramps","Women's Health",[30,33,28,31],"Dysmenorrhea","NOT_YET_RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2026-12",{"date":42,"type":22},"2027-03",{"name":44,"class":45},"University of California, Davis","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100635684","intervention-in-executive-functions-and-emotional-self-regulation-in-adolescents-with-primary-dysmenorrhea-100635684","NCT07555886","Intervention in Executive Functions and Emotional Self-Regulation in Adolescents With Primary Dysmenorrhea","Evaluación de Una intervención psicológica Sobre Funciones Ejecutivas cálidas y autorregulación Emocional en Adolescentes Con Dismenorrea Primaria","CALMA","Inclusion criteria Gender: menstruating individuals in late adolescence.\n\n* Age: 15 to 19 years.\n* Estimated IQ above 80.\n* With painful menstrual cycles (primary dysmenorrhea) without a prior gynecological diagnosis.\n* Students at the institution selected for the intervention.\n* Written expression of willingness and interest in participating in the program (informed consent in the case of minors)\n* Informed consent signed by parents (in the case of minors) or by the participants (in the case of adults).\n* Attendance of at least 70% of the intervention sessions.\n\nExclusion criteria\n\n* Ages other than those previously indicated.\n* An estimated IQ below 80.\n* A prior gynecological diagnosis of a condition other than dysmenorrhea.\n* Pharmacological or hormonal treatment that could, in and of itself, interfere with executive functions, pain perception, and emotional regulation.\n* With psychiatric and\u002For neurological conditions that, in and of themselves, affect executive functions and emotional regulation.\n* With pain-free menstrual cycles.\n* Lack of interest or willingness to participate in the program\n* Lack of informed consent or assent.\n\nElimination criteria\n\n* Voluntary withdrawal from the program.\n* Missing more than 30% of the sessions.\n* Withdrawal of informed consent (personal, from guardians, or institutional).\n* Receiving a diagnosis that meets any of the exclusion criteria during the -intervention program.","15 Years",{"count":56,"type":22},35,[25],"Primary dysmenorrhea is one of the most common gynecological conditions during adolescence and is associated not only with recurrent menstrual pain, but also with emotional disturbances and difficulties in behavioral regulation. Various studies have indicated that hot executive functions-linked to emotional processing, decision-making in affective contexts, and impulse control-play a relevant role in the experience of and coping with pain.\n\nThe present project aims to design and evaluate the effectiveness of a structured psychological intervention focused on strengthening hot executive functions and emotional self-regulation in adolescents with primary dysmenorrhea. A quasi-experimental design with pre- and post-intervention assessment is proposed, using validated instruments to measure pain intensity, coping strategies, and executive-emotional performance. The intervention is expected to contribute to a reduction in perceived pain and to improvements in emotional regulation strategies, promoting more adaptive coping. This study seeks to provide empirical evidence on brief psychological interventions aimed at the comprehensive management of menstrual pain in adolescent populations.",[30],[61,62,63,64,65],"Menstruation","Adolescents","Emotional regulation","Hot executive functioning","Primary dysmenorrhea.","2026-05-13",{"date":68,"type":38},"2026-05-18",{"date":70,"type":22},"2026-08-30",{"date":72,"type":22},"2028-03-30",{"name":74,"class":45},"Universidad Autonoma de Baja California",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":16,"sex":17,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":101,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":75},"100628155","effectiveness-of-an-mhealth-innovation-on-the-impact-of-menstrual-complaints-in-adolescents-100628155","NCT07457957","Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents","The Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents - A Randomised Controlled Trial","MGA","Inclusion Criteria:\n\n* Dutch, English, Turkish or Moroccan-Arabic speaking\n* Post menarche\n* Access to a smartphone or tablet with iOS or Android operating system\n\nExclusion Criteria:\n\n* Amenorrhea\n* Pregnancy\n* No menstrual bleeding or withdrawel bleeding in the 3 months prior to inclusion.\n* Previously or currently under treatment by a health care provider for menstrual complaints","12 Years","21 Years",{"count":87,"type":22},874,[25],"The aim of this study is to improve menstrual health-related quality of life in adolescents by using a mobile menstrual health tracker. We will perform a randomized controlled trial to evaluate the (cost)-effectiveness of this mHealth intervention.",[33,91,30,92,93,94,95,96,97,98,99,100],"Heavy Menstrual Bleeding","Menstrual Bleeding, Heavy","Menstrual Discomfort","Menstrual Cycle Abnormal","Menstrual Disorder","Menstrual Health","Mobile Application","mHealth","Menstrual Health Intervention","Adolescent",[102,98,103,100,104],"randomized clinical trial","Menstrual health","Menstrual Tracker App","2026-03-04",{"date":107,"type":38},"2026-03-09",{"date":109,"type":22},"2026-02-16",{"date":111,"type":22},"2029-05-31",{"name":113,"class":45},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)"]